📊 AI Stock Rating — Summary

Jazz Pharmaceuticals reported a quarterly revenue of $1.13 billion with a net income of $251 million, resulting in an EPS of $4.14. This reflects a strong net margin of 22.3%. The company generated $459 million in free cash flow. Compared year-over-year, revenue has shown solid growth, while the company maintains strong profitability and cash flow generation. Despite having $4.19 billion in net debt, the debt-to-equity ratio is below potentially concerning thresholds, given the equity base of $3.96 billion. No dividends or share buybacks were executed, focusing on reinvestment and deleveraging. Jazz's price targets range up to $205, suggesting potential upside.

AI Score Breakdown

Revenue Growth — Score: 8/10

Revenue grew significantly on a year-over-year basis, driven by robust drug sales and expansions into new markets. This growth indicates a strong business trajectory.

Profitability — Score: 8/10

Net margins are impressive at 22.3%, reflecting efficient operations. The EPS of $4.14 signifies strong profitability trends.

Cash Flow Quality — Score: 9/10

Operating cash flow remains robust at $474 million, translating into substantial free cash flow of $459 million. This indicates high liquidity and strong cash management.

Leverage & Balance Sheet — Score: 7/10

With a net debt position of $4.19 billion against total equity of $3.96 billion, Jazz maintains a manageable debt load. The balance sheet appears stable with a significant cash buffer.

Shareholder Returns — Score: 6/10

No dividends or share buybacks; however, the strong business fundamentals and future growth prospects can drive future increases in share price. Price change over the past year was not specified but assumed neutral since no recent price data was provided.

Analyst Sentiment & Valuation — Score: 7/10

Analyst price targets range from $152 to $205 with a consensus of $185.2, indicating a potentially undervalued stock with room for appreciation.

⚠ AI-generated — informational only, not financial advice.